HPV genotyping: need of the hour for cervical cancer screening

Abstract

Objectives: Cervical cancer is the most common cancer and leading cause of cancer deaths in women in developing countries. India shares about one-fourth of the global burden of cervical cancer and almost all cases harbour high risk Humanpapilloma virus (HPV) infection. This is a unique cancer in the sense that it is totally attributable to the effects of an infectious virus. Therefore, the present study was undertaken to evaluate the distribution of HPV genotypes in a rural area of Punjab, with the aim of identifying the most frequent HPV genotypes associated with different cervical lesions in this population. Materials and Methods: The study was conducted over a period of two years i.e. from January2013 to January 2015, on women attending obstetrics and gynaecology department of a tertiary care hospital. One hundred sixty consecutive scrape samples or cervical brushings were collected from women presenting with any type of cervical lesions. DNA was extracted from the clinical sample using Hybribio DNA extraction kit. Hybribio HPV genoarray test kit was used to genotype the HPV risk groups. Results: Out of 160 cervical brushings collected over a period of two years, 17 (10.6%) were positive for HPV genotypes. Among the latter, HPV18 genotype was observed in 7(41.17%), HPV16 genotype in 3 (17.65%) and HPV53 genotype in 2(11.76%). One of the genotypes 68, 52, 39, 33 and 15 were present in rest of the samples. Conclusion: HPV genotypes 18 followed by 16 were the most common genotypes found in the present study. HPV vaccination along with HPV based screening may go a long way in controlling cervical cancer in India. J Microbiol Infect Dis 2016;6(4): 168-171

Keywords

• HPV,Cervical cancer,Screening,Genotyping

References

1. 1. Burd EM. Human papilloma virus and cervical cancer. Clin Microbiol Rev 2003; 16:1-17.
2. 2. Shanta V, Krishnamurthi S, Gajalakshmi CK, et al. Epidemiology of cancer of the cervix: global and national perspective. J Indian Med Assoc.2000; 98:49-52.
3. 3. Speich N, Schmitt C, Bollmann R, et al. Human Papilloma Virus study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from west German area. J Med Microbiol 2004; 53:125-128.
4. 4. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
5. 5. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
6. 6. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-998.
7. 7. Clifford GM, Smith JS, Plummer M, et al. Humanpapillomavirus types in invasive cervical cancer worldwide: a metaanalysis.Br J Cancer 2003;88:63-73
8. 8. MolanoM, Van den Brule A, Plummer M, et al. HPV study group. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population based, 5 years follow-up study. Am J Epidemiol 2003; 158:486-494.

9. 9. Walboomers JM, Jacobs MV, Manos MM, et al. Human papilloma virus is necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
10. 10. Munoz N, Bosch FX, de Sanjose S, et al. International agency for research on cancer. Multicenter Cervical cancer study group. Epidemiological classification of human papilloma virus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
11. 11. Spitzer M. Cervical screening adjuncts: recent advances. Am.J.Obstet. Gynecol 1998; 179:544-556.
12. 12. Duttagupta C, Sengupta S, Roy M, et al. Are Muslim women less susceptible to oncogenic human papillomavirus infection. A study from rural eastern India. Int J Gynaecol Cancer 2004; 14:293-303.
13. 13. Aggarwal R, Gupta S, Nijhawan R, et al. Prevalence of high -risk human papillomavirus infections in women with benign cervical cytology: a hospital based study from North India. Indian J. Cancer 2006; 43:110-116.
14. 14. Basu P, Roychowdhury S, Bafna UD, et al. Human papillomavirus genotype distribution in cervical cancer in India: results from a multi-centre study. Asian Pac J Cancer Prev 2009; 10:27-34.
15. 15. De Mendez MT. Prevalence of Human Papillomavirus (HPV) Genotypes and Multiple Infections in Routine Cervical Cancer Screening in a Spanish Regional Population. SOJ Microbiol Infect Dis 2013;1 (1):6.
16. 16. Y.Lazcano-Ponce E, Herrero R, Munoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91:412-420.
17. 17. Munoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111:278- 285.
18. 18. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 265:K29-K41.
19. 19. Saslow D, Solomon D, Lawson HW, et al. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Cancer J Clin 2012; 62(3):147-172.
20. 20. Trottier H, Franco EL. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 2006; 12: S462-S472.
21. 21. Franco EL, Cuzick J. Cervical cancer screening following prophylactic humanpapillomavirus vaccination. Vaccine 2008; 26: A16-A23.
22. 22. No JH, Kim MK, JeonYT, Kim YB, Song YS. Human papillomavirus vaccine: widening the scope for cancer prevention. Mol Carcino 2011; 50(4): 244-253.